Time to Market KPI

Time to Market (TTM) is crucial for assessing how quickly a company can deliver products or services to customers.

A shorter TTM often correlates with improved operational efficiency and enhanced customer satisfaction.

Companies that excel in TTM can capitalize on market opportunities faster, leading to increased market share and revenue growth.

This KPI directly influences the ability to respond to customer needs and adapt to changing market dynamics.

By streamlining processes, organizations can achieve better forecasting accuracy and strategic alignment.

Ultimately, effective management of TTM enhances overall financial health and drives business outcomes.

How Time to Market Connects to Your Strategy

Time to Market carries the most weight where speed to launch is the core discipline. It is the top priority metric in both the Product Lifecycle Management KPI group and the Research & Development (R&D) KPI group. In Product Lifecycle Management it leads a set whose next headline co-metrics are Product Development Efficiency, Return on Investment (ROI), and Customer Satisfaction Index. In Research & Development (R&D) it sits ahead of Product Quality, Customer Satisfaction, and Innovation Rate. In the Product Development KPI group it ranks second, behind Development Velocity and ahead of Product Adoption Rate and Defect Rate.

It stays prominent in two life sciences settings. It is the fourth priority metric in the Biotechnology KPI group, where Research & Development Pipeline Strength, Clinical Trial Success Rate, and Regulatory Approval Success Rate rank above it, and fourth again in the Pharmaceuticals KPI group, behind Research & Development Expenditure, Clinical Trial Success Rate, and FDA Approval Rate. Here the metric answers to regulatory gates, not just internal cadence.

Across the rest of its membership the metric matters, but as a supporting signal rather than the headline. It ranks in the low tens in the Innovation Investment ROI KPI group, tenth, alongside Return on Innovation Investment (ROI2) and Time to Profitability, and in the Electronics KPI group, thirteenth, next to Revenue Growth Rate and Gross Margin. It appears in the mid ranks of the Competitive Analysis KPI group, fourteenth, and the Analytics KPI group, sixteenth. From there the long tail runs through the twenties and beyond, in industry KPI groups such as Agriculture, Business Growth Metrics, Competitive Benchmarking, Product Management, Semiconductors, Engineering, Mining, Fashion, Textiles and Apparel, Consumer Packaged Goods, FoodTech, Natural Gas, Warehousing/Distribution, and Aerospace & Defense, and it thins to a minor entry in Manufacturing, fiftieth, and Building Materials, fifty-third, where launch cadence is far from the daily concern.

On the balanced scorecard this is an internal process metric, so it reads as leading: it moves before the financial results that follow a launch. That is also where the friction lives. In Research & Development (R&D) the group pairs it with Product Quality, and speed pulls against quality directly. Compress the schedule and First-Pass Yield and Defect Rate tend to suffer, which is why the R&D best practice text ties Time to Market gains to On-Time Delivery rather than to raw acceleration. In Product Development the same tension shows up against Defect Rate: faster releases with rising defects signal rushed delivery, not genuine velocity.

Measuring Time to Market in Practice

The honest version of this metric starts with an explicit clock. Decide where it starts, at idea approval, at formal project kickoff, or at first committed spend, and where it stops, at first customer availability, at general availability, or at a regulatory clearance. The canonical formula here runs from concept to market availability, so pin both ends in writing before anyone reports a number, because most disagreement about this metric is really disagreement about the endpoints.

The underlying data rarely lives in one system. Concept and approval dates sit in portfolio or stage gate tools, engineering effort sits in the sprint or project system, and launch dates sit with product marketing or, in regulated settings, with the regulatory affairs team. Join them on a stable project identifier, and record the source of each date so a disputed timeline can be reconstructed. Do not stitch dates from tools that define a launch differently.

Several definitional forks come straight from how the tracked sources are cut. Threshold versus average is one: a regulatory clearance window is a gate you must clear, while a development average is a central tendency across projects, and the two do not combine. Population is another: a device clearance path, a drug approval path, and a general new product cycle are distinct populations with distinct clocks, so never pool them into a single figure. Company size and era matter too, since a mixed size cross-industry baseline from an earlier period will not describe a modern regulated program.

Segment before you compare. Split by product type, by whether the path is regulated, and by whether a launch was a genuine new product or an incremental feature, because blended averages hide the cases that actually drive the number. The pitfalls that most distort this metric: cancelled or paused projects quietly dropping out, which flatters the average by removing the slow cases; restarted projects that reset the clock and erase real elapsed time; and counting a soft or limited launch as full availability, which understates the true duration. Fix the counting rule for each of these before you publish a trend.

Common Pitfalls

Many organizations underestimate the impact of TTM on overall business performance. Delays in product launches can stem from various missteps that hinder progress.

• Inadequate resource allocation often leads to bottlenecks in development. Teams may lack the necessary tools or personnel to meet deadlines, causing delays in product readiness.
• Failure to prioritize projects can result in scattered focus. When teams juggle too many initiatives, critical tasks may fall behind, extending TTM unnecessarily.
• Poor communication across departments can create misunderstandings. Misalignment between marketing, development, and sales teams often leads to delays in product launches.
• Neglecting to incorporate customer feedback early can lead to costly revisions. Without understanding market needs, products may require significant changes post-development, extending TTM.

Improvement Levers

Streamlining processes can significantly enhance TTM, enabling quicker responses to market demands.

• Adopt agile methodologies to improve flexibility and responsiveness. Agile practices allow teams to iterate quickly, reducing time spent on revisions and enhancing product quality.
• Invest in project management tools to enhance visibility and accountability. These tools can help track progress, allocate resources effectively, and identify potential roadblocks early.
• Foster cross-functional collaboration to align goals and streamline workflows. Regular check-ins between departments can mitigate miscommunication and ensure everyone is on the same page.
• Implement a robust customer feedback loop to inform product development. Engaging customers early can help teams prioritize features that drive value, reducing the need for extensive revisions.

KPI Depot is trusted by consulting, strategy, finance, and analytics teams at leading organizations worldwide, including those listed below.

Time to Market Benchmarks

We have 7 relevant benchmarks in our benchmarks database.

Browse the Top Benchmarked KPIs in Research & Development (R&D)

Reading the Benchmarks for Time to Market

The seven benchmark rows on this page trace back to a smaller set of source bodies, and they do not all measure the same thing. Read the source names before you read any figure into them.

Four of the seven rows lean on a single body: Applied Clinical Trials (Tufts CSDD benchmarks). That is one vendor cross-cut, not four independent confirmations. Those rows describe drug approvals segmented by therapeutic area, and one narrows to new drugs and biologics cleared through FDA CDER over a defined study window. When one source supplies most of the rows, agreement between them tells you about that source's method, not about the wider market.

The other three rows come from different places and measure different populations. The U.S. Food and Drug Administration row sets a review threshold for 510(k) submissions in medical devices, framed against MDUFA performance goals, so it captures a regulatory clearance window rather than end to end product time to market. JACC: Basic to Translational Science reports across both medical devices and drugs, blending two development paths that rarely share a timeline. The Journal of Product Innovation Management row is the one genuinely cross-industry entry, drawn from new product development projects of mixed company size, and it is the oldest, so its baseline reflects an earlier era of development practice.

The practical caution: several of these sources measure clinical trial or drug development timelines, not general product time to market. Definitions, populations, and geography differ from row to row. A drug approval clock, a device clearance window, and a new product development cycle are three different measurements wearing one label. Before trusting any external figure, confirm which stage the source starts and stops the clock, which population it counts, and whether its industry and time period resemble yours. Numbers that float free of those anchors are not comparable, which is the whole reason source attributed data is worth paying for.

OKRs That Use Time to Market

This KPI works as a key result under objectives that already name it in the groups' own OKR text, so the framings below stay close to the source rather than inventing a fit.

In the Research & Development (R&D) KPI group, the objective Accelerate product innovation while ensuring market readiness uses Time to Market as a key result directly. Keep the key result directional: shorten Time to Market toward a target the team sets, paired with On-Time Delivery so the schedule holds under pressure. The group's own best practice guidance makes that pairing explicit, which guards against buying speed with slipped milestones.

In the Product Lifecycle Management KPI group, the objective Accelerate product delivery while maintaining development excellence lists Time to Market alongside Product Development Efficiency and First-Pass Yield. A workable framing keeps Time to Market as the headline key result while holding First-Pass Yield steady, so a faster clock does not quietly raise rework.

For regulated settings, the Pharmaceuticals KPI group offers the objective Shorten time to market by streamlining clinical and regulatory processes, where Time to Market is a key result tied to Regulatory Compliance Rate. Here the directional key result is to compress the timeline while compliance holds or improves, since in this domain speed that trips a submission error is no speed at all.

See OKR Examples for Research & Development (R&D)

KPI Categories

This KPI is associated with the following categories and industries in our KPI database: